Neurology and Neurosurgery: Clinical Studies Open For Enrollment
Clinical Studies Open for Enrollment
Eligibility
- 18 years to 90 years of age
- Pre-morbid Modified Rankin Score less than or equal to 3
- Confirmed diagnosis of subacute or chronic subdural hematoma
- Completed informed consent
- Meets criteria for Surgery or Observation Cohort
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT04402632
Principal Investigator
Justin Santarelli, MD
Contact for Study Screening
Cristina.Falo@wmchealth.org
Middle Meningeal Artery EMbolization for the Treatment of SuBduRal HemAtomas with TRUFILL® n-BCA (MEMBRANE)
Eligibility
- 18 years to 90 years of age
- Pre-randomization mRS less than or equal to 3
- Confirmed diagnosis of chronic subdural hematoma
- Completed informed consent
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT04816591
Principal Investigator
Fawaz Al-Mufti, MD
Contact for Study Screening
Cristina.Falo@wmchealth.org
A Prospective, Multi-Center, Single Arm Study to Obtain "Real World" Clinical Data and Characterize the Acute and Long-Term Performance of the Micrusframe and Galaxy Coils Including the Pulserider Aneurysm Neck Reconstruction Device for the Endovascular Treatment of Intracranial Aneurysms (STERLING)
Eligibility
- Patient is between 21 and 80 years of age
- Patient has an intracranial saccular aneurysm, ruptured or unruptured, suitable for embolization with coils
- Patient is able and willing to comply with protocol and follow-up requirements
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT03642639
Principal Investigator
Fawaz Al-Mufti, MD
Contact for Study Screening
Cristina.Falo@wmchealth.org
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Eligibility
- Patients who undergo maximum safe resection of intracranial neoplasm(s) AND implantation of GammaTiles
- Willing and able to provide informed consent and to participate in all evaluations
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT04427384
Principal Investigator
Simon Hanft, MD
Contact for Study Screening
Monique.Carrero-Tagle@wmchealth.org
A Prospective Non-Invasive Study of Cerebral Blood Flow Velocity Morphology for Quantification of Intracranial Pressure (ICP)
Eligibility
- Subject is between 18-80 years of age
- Subject with diagnosis of Traumatic Brain Injury (TBI) or Stroke (i.e. Hemorrhagic Stroke)
- Subject with invasive ICP monitor (ventriculostomy, or other)
- Subject or Legally Authorized Representative has the ability to provide informed consent and comply with the protocol.
Enrollment Status: Actively enrolling
Study Information
NovaSignal.com
Principal Investigator
Fawaz Al-Mufti, MD
Contact for Study Screening
Cristina.Falo@wmchealth.org
A Prospective, Multicenter Study Assessing the Embolization of Intracranial Aneurysms using WAVE™ Extra Soft coils, a part of the Penumbra SMART COIL® System (SURF)
Eligibility
- Patient is at least 18 years of age
- Patient having embolization of intracranial aneurysms
- WAVE Extra Soft Coil is final finishing coil
- Penumbra SMART COIL System accounts for at least 75% of total number of coils implanted
- Informed consent obtained per IRB/EC requirements
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT04106583
Principal Investigator
Chirag Gandhi, MD
Contact for Study Screening
Cristina.Falo@wmchealth.org
A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT 2)
Eligibility
- Adults (18-85 years) with the final diagnosis of an acute ischemic stroke
- NIH Stroke Scale Score (NIHSS) equal to or greater than 6
- Last known well to groin puncture or medical management between 0 - 24 hours
- Pre-stroke modified Rankin Scale score (mRS) of 0-1
- Eligible for thrombectomy or medical management
- Signed Informed Consent obtained
- Subject willing to comply with the protocol follow-up requirements
- Anticipated life expectancy of at least three months
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT03876457
Principal Investigator
Chirag Gandhi, MD
Contact for Study Screening
Cristina.Falo@wmchealth.org
Pediatric Neurology: Clinical Studies Open for Enrollment
Responsive Stimulation for Adolescents with Epilepsy (RESPONSE) Study
Eligibility
- Patient is between 12-17 years of age
- Disabling motor simple partial seizures, complex partial seizures and/or secondary generalized seizures
- Seizures that are distinct, stereotypical event that can be reliably counted
- Subject had an average of three or more disabling seizures and/or generalized seizures over the two most recent consecutive 30 days.
- Subject failed treatment with a minimum of 2 AED (anti-epileptic drugs)
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT04839601
Principal Investigator
Steven Wolf, MD
Contact for Study Screening
ppena_ar@nymc.edu
dzogejan@nymc.edu
An Open-Label, Single-Dose, Pharmacokinetics Study of VALTOCO® with Open-Label Safety Period in Pediatric Subjects with Epilepsy
Eligibility
- Patient is between two to five years of age
- Clinical diagnosis of epilepsy
- Partial or generalized epilepsy with motor seizures or seizures with clear alteration of awareness for which rescue medications are used at least once a month for the last three months
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT05076838
Principal Investigator
Steven Wolf, MD
Contact for Study Screening
ppena_ar@nymc.edu
dzogejan@nymc.edu